Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ANIP 
ANI Pharmaceuticals Inc (ANIP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: ANIP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $107
1 Year Target Price $107
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 34.57% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.02B USD | Price to earnings Ratio - | 1Y Target Price 107 |
Price to earnings Ratio - | 1Y Target Price 107 | ||
Volume (30-day avg) 6 | Beta 0.58 | 52 Weeks Range 52.50 - 99.50 | Updated Date 10/31/2025 |
52 Weeks Range 52.50 - 99.50 | Updated Date 10/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.69 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When - | Estimate 1.7 | Actual - |
Profitability
Profit Margin -1.37% | Operating Margin (TTM) 7.18% |
Management Effectiveness
Return on Assets (TTM) 1.09% | Return on Equity (TTM) -2.17% |
Valuation
Trailing PE - | Forward PE 11.1 | Enterprise Value 2409753725 | Price to Sales(TTM) 2.7 |
Enterprise Value 2409753725 | Price to Sales(TTM) 2.7 | ||
Enterprise Value to Revenue 3.22 | Enterprise Value to EBITDA 27.06 | Shares Outstanding 22291672 | Shares Floating 18077257 |
Shares Outstanding 22291672 | Shares Floating 18077257 | ||
Percent Insiders 10.13 | Percent Institutions 95.87 |
Upturn AI SWOT
ANI Pharmaceuticals Inc
Company Overview
History and Background
ANI Pharmaceuticals, Inc. was founded in 2003. It focuses on developing, manufacturing, and marketing branded and generic pharmaceutical products. The company has grown through acquisitions and internal product development, becoming a specialty pharmaceutical company.
Core Business Areas
- Generic Pharmaceuticals: Development, manufacturing, and marketing of generic pharmaceutical products. Focus on niche and complex generics.
- Branded Pharmaceuticals: Development, marketing, and sale of branded pharmaceutical products, often through product acquisition or internal development.
- Contract Manufacturing: Manufacturing pharmaceutical products for other companies on a contract basis.
Leadership and Structure
Nikhil Lalwani is the CEO. The company has a typical corporate structure with functional departments such as R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Estratest: A branded estrogen and testosterone combination product used to treat menopausal symptoms. Market share is difficult to pinpoint due to the fragmented hormone therapy market. Competitors include generic versions of hormone therapy products, as well as branded therapies from companies like Mylan (now Viatris) and Teva.
- Cortrophin Gel: An adrenocorticotropic hormone (ACTH) product indicated for various conditions. Revenue stream is significant. Competitors include synthetic corticosteroids and other ACTH therapies, although Cortrophin Gel has a unique position in the market.
- Market Data: The product's market share fluctuates but holds a notable position in a niche area.
- Vancomycin Oral Solution: Used to treat Clostridium difficile-associated diarrhea and staphylococcal enterocolitis. Competitive environment includes generic versions from companies like Teva and Mylan (Viatris).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, strict regulatory oversight (FDA), pricing pressures, and a constant need for innovation. Generic pharmaceuticals face pricing erosion, while branded products rely on patent protection and marketing.
Positioning
ANI Pharmaceuticals focuses on niche generic and branded pharmaceuticals, often targeting markets with limited competition or complex manufacturing requirements. This strategy aims to provide higher margins than traditional generic markets.
Total Addressable Market (TAM)
The global pharmaceutical market is valued at over $1 trillion. ANI Pharmaceuticals targets specific segments like hormone therapies, injectable drugs, and controlled substances. While ANIu2019s total addressable market is significantly smaller than the overall pharmaceutical market, its niche focus allows for a strong competitive position in targeted segments.
Upturn SWOT Analysis
Strengths
- Niche product portfolio
- Specialized manufacturing capabilities
- Strong track record of acquisitions
- Experienced management team
Weaknesses
- Reliance on a limited number of key products
- Exposure to generic competition
- Dependence on acquisitions for growth
- High debt levels
Opportunities
- Acquisitions of complementary products or companies
- Expansion into new therapeutic areas
- Development of new generic products
- Increased demand for niche pharmaceuticals
Threats
- Increased competition from generic manufacturers
- Pricing pressures from payers
- Regulatory changes
- Product liability lawsuits
Competitors and Market Share
Key Competitors
- TEVA
- VTRS
- ENDP
Competitive Landscape
ANI competes primarily with generic pharmaceutical companies, branded pharmaceutical companies, and contract manufacturers. Its competitive advantage lies in its niche product portfolio and specialized manufacturing capabilities.
Major Acquisitions
Alimera Sciences' New River Pharmaceuticals
- Year: 2023
- Acquisition Price (USD millions): 82.5
- Strategic Rationale: The acquisition adds an orphan-designated product targeting a specific patient population, expanding ANI's portfolio in ophthalmology and providing revenue diversification.
Growth Trajectory and Initiatives
Historical Growth: ANI has grown through acquisitions and organic product development. Historical performance has been variable due to the nature of the pharmaceutical industry.
Future Projections: Future growth is expected to come from new product launches, acquisitions, and increased sales of existing products. Analyst estimates vary depending on market conditions and company performance.
Recent Initiatives: Recent initiatives include acquisitions of new products and companies, as well as investments in R&D and manufacturing capabilities.
Summary
ANI Pharmaceuticals operates in a competitive niche pharmaceutical market, capitalizing on specialized manufacturing and strategic acquisitions. Its focus on generic and branded products in less crowded spaces offers potential for higher margins but also carries risks associated with competition and regulatory changes. Strong financial management and further diversification will be crucial for long-term stability. The company benefits from a proven strategy of acquiring complementary businesses.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
- Company Website
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions can change rapidly, and actual results may differ.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ANI Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Baudette, MN, United States | ||
IPO Launch date 2000-05-05 | President, CEO & Director Mr. Nikhil Lalwani | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 897 | |
Full time employees 897 | |||
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group purchasing organizations, specialty pharmacies, hospitals, clinics, and physicians. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.